Human leukocyte antigen and T-cell receptor (HLA and TCR)

The interaction between **human leukocyte antigen (HLA)** and the **T-cell receptor (TCR)** is fundamental to adaptive immunity. HLA molecules, encoded by the highly polymorphic major histocompatibility complex (MHC) on chromosome 6, present short peptide antigens on the cell surface, enabling immune surveillance by T cells. The TCR, a membrane-bound heterodimer comprising variable alpha and beta (or less commonly, gamma and delta) chains associated with CD3 complexes, specifically recognizes peptide-HLA (pHLA) complexes. This highly specific binding triggers signaling cascades via immunoreceptor tyrosine-based activation motifs (ITAMs) resulting in T cell activation, proliferation, and effector functions such as targeted cell killing or cytokine release[1][2][3][4][5][7]. HLA-TCR interaction drives the immune system’s ability to distinguish self from non-self, eliminate infected or malignant cells, and generate immunological memory. Dysregulation or evasion of this interaction leads to diseases such as cancer, infection, autoimmunity, and transplant-related complications. Therapeutic strategies often exploit or modulate this axis, as seen in immune checkpoint inhibition, engineered T-cell therapies, and histocompatibility matching[2][4][7]. Note: This entry combines two distinct though inseparable immune protein families—HLA (a gene-protein system) and TCR (a multimeric protein receptor). For most structured purposes, these are classified and targeted separately, and the term "HLA and T-cell receptor" is not a precise canonical target name but denotes the immune synapse or the axis by which adaptive immune specificity is mediated. A more structured approach would model HLA and TCR each as their own canonical targets, unless your application requires them as a functional unit (e.g., for describing the immune synapse in adoptive therapy or epitope mapping research)[4][5][7].

Other names

HLA-TCR axisHLA/TCR complexMHC-TCR interactionMajor histocompatibility complex and T-cell receptor interaction

Blockade of TCR engagement with peptide-HLA (pHLA); Inhibition or activation of downstream TCR signaling pathways; Enhancement of T cell recognition of tumor/HLA-epitope complexes; Disruption of antigen presentation (HLA modulation); Induction of tolerance (HLA-restricted therapies)